Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases

~ Today, Novo Nordisk and Evotec SE announced the launch of LAB eN² (pronounced Lab ee – en – squared), a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics. The focus is on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.

LAB eN² is a unique engagement model that combines Evotec's multimodality drug discovery and preclinical development capabilities with Novo Nordisk's therapeutic, clinical, and commercial expertise. Already, four academic institutions have signed on to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.

Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Boston said: "At Novo Nordisk, we are always looking for what is next in disruptive science. Many great ideas are started in academia, but translational research and moving the idea to the next stage remains a challenge. With the launch of LAB eN² and our collaboration with these institutions, there is a tremendous opportunity to address this longstanding gap and help move innovative science forward and seek to make a significant impact on people living with chronic conditions."

More on Boston Chron
The prevalence of cardiometabolic diseases is drastically increasing worldwide; about 537 million adults live with diabetes1 while cardiovascular diseases are a leading cause of death globally2. The journey from academic idea to treatments for people living with chronic conditions requires drug discovery and development capabilities as well as large investments of time, resources, and funding that can be difficult to acquire. LAB eN² was created to provide a solution-focused pathway for academic researchers by providing funding, scientific expertise, and technology to help advance product concepts through preclinical proof of concept. Successful therapeutic product candidates may then be selected by Novo Nordisk for further investment and development.

Thomas Hanke, EVP & Head of Academic Partnerships at Evotec said: "We are enthusiastic about the launch of LAB eN² with our partner Novo Nordisk. Based on leading-edge research and with access to Evotec's end-to-end integrated platform, we are confident that LAB eN² will accelerate promising and innovative therapeutic concepts from bench to bedside in disease areas with significant unmet need."

More on Boston Chron
Participating academic institutions will work under a common governance framework which was established in discussions with the institutions Harvard University, Mass General Brigham, Yale University; research concepts will be selected for LAB eN² support based on proposals from investigators at these participating academic institutions which will be jointly developed by the academic investigators along with Evotec & Novo Nordisk's Bio Innovation Hub in Cambridge Massachusetts. For more details on LAB eN² please visit
Filed Under: Business

Show All News | Report Violation


Latest on Boston Chron